# Numab Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/numab-therapeutics

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.numab.com
- Total disclosed funding: $194M
- Latest round: Series C (Jan 9, 2025)
- Investors on record: 11

## About

Numab Therapeutics AG, based in Switzerland, focuses on developing innovative multi-specific antibody-based immunotherapies targeting inflammation and cancer, utilizing proprietary platforms to create customized therapeutic solutions.Founded in 2011 and headquartered in Zurich, Switzerland, Numab Therapeutics AG specializes in immunotherapy development. The company has successfully raised CHF 50.000 mn in its SERIES C funding round as of January 9, 2025, led by notable investors including Cormorant Asset Management and HBM Partners. Peter Lichtlen is the founder, with David Urech serving as CEO.Numab Therapeutics AG specializes in developing multi-specific antibody-based immunotherapies with a focus on inflammation and cancer. Their flagship products leverage two proprietary platforms, ?-Cap™ and MATCH™, aiding in the creation of tailored therapeutic options. Notably, their lead candidate NM26 targets IL-4Ra and IL-31 for atopic dermatitis and related disorders. The company collaborates with pharmaceutical partners like Kaken Pharmaceutical Co., Ltd in Japan to enhance product development and reach key markets across Europe, North America, and Asia.Numab Therapeutics AG generates revenue through strategic collaborations with pharmaceutical companies for therapy development and commercialization. Their revenue model is primarily B2B, relying on partnerships that fund research and clinical development in return for licensing rights or profit-sharing agreements. This approach is critical for advancing their pipeline and ensuring a stable revenue flow as their products progress through clinical trials.Numab Therapeutics AG plans to further its growth by launching new products, including advancing NM26 through clinical trials. The recent CHF 50.000 mn raised in SERIES C funding will support these initiatives, enhancing their capacity for product development. The company aims to expand its market presence in Europe, North America, and Asia by strategically collaborating with pharmaceutical partners and advancing their therapeutic offerings in these regions.

## Funding rounds

- Series C, Jan 9, 2025, $55M — HBM Partners, Novo Holdings, Forbion, BlackRock, RTW Investments, BVF Partners, Cormorant Asset Management, Octagon Capital Advisors
- Series C, May 12, 2022, $5.1M — HBM Partners
- Series C, May 12, 2021, $111M — HBM Partners, Novo Holdings, Forbion, BlackRock, RTW Investments, BVF Partners, Cormorant Asset Management, Octagon Capital Advisors
- Series B, Mar 9, 2020, $23M — Mitsubishi UFJ Capital, Eisai Co, 3SBio Inc.

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B
- Eisai Co — Series B
- 3SBio Inc. — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Novo Holdings — Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series C